Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment

There is no fulltext present in this item.

Title:	Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment
Author(s):	Heskamp, S. ; Boerman, O.C. ; Molkenboer-Kuenen, J.D.M. ; Koornstra, R.H.; Linn, S.C.; Oyen, W.J.G. ; Graaf, W.T.A. van der ; Laarhoven, H.W.M. van
Publication year:	2014
Source:	Molecular Imaging and Biology, vol. 16, (2014), pp. 529-537
ISSN:	1536-1632
DOI:	https://doi.org/10.1007/s11307-014-0723-6
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/137834
Display more details
Subject:	Radboudumc 17: Women's cancers RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 19: Nanomedicine RIHS: Radboud Institute for Health Sciences Radboudumc 19: Nanomedicine RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Nuclear Medicine Radiology & Nuclear Medicine Medical Oncology
Journal title:	Molecular Imaging and Biology
Volume:	vol. 16
Page start:	p. 529
Page end:	p. 537
Abstract:	The aim was to assess changes in insulin-like growth factor 1 receptor (IGF-1R) expression with immunoSPECT/CT and to study the dynamics of IGF-1R expression of human breast tumors during endocrine treatment.Mice with MCF-7 xenografts were treated with estradiol or tamoxifen, and IGF-1R expression was measured by immunohistochemistry and immunoSPECT/CT using (111)In-R1507 (anti-IGF-1R antibody). Moreover, IGF-1R expression was analyzed immunohistochemically on 22 human breast tumors, treated preoperatively with endocrine therapy.Estradiol resulted in an increased expression of IGF-1R, as measured by immunohistochemistry and immunoSPECT/CT. In contrast, tamoxifen resulted in a downregulation of IGF-1R, whereas this could not be measured with immunoSPECT/CT. A downregulation was also detectable in 9 out of 22 (41 \%) human breast tumors after endocrine therapy.Anti-estrogen treatment can cause a reduction in membranous IGF-1R expression. Based on these results, a combination of anti-IGF-1R antibodies with anti-estrogen therapy might not be a rational treatment strategy.